본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

A Novel Drug Delivery System Design for Meloxicam

Kim, Hyun-Jo    (Product Development & Planning, Kolon Pharm. Inc.   ); Lee, Il-Kyu    (R&D Center, Daejun Research Complex  );
  • 초록

    A drug delivery system(DDS) for practically insoluble meloxicam was developed and evaluated by dissolution study. A novel DDS is two layered system, where the first layer is consisted of gas-forming agent for an immediate release and the second layer is composed of metolose SR(HPMC) for sustained release. This bilayered tablets were manufactured by using manual single punch machine. The results of dissolution study showed an initial burst release followed by sustained release for the experimental period time. From a pharmaceutical point of view, the designed DDS for meloxicam would be informative system in terms of poorly soluble analgesic medicines.


  • 주제어

    Drug delivery system .   practically insoluble drug .   meloxicam .   effervescent tablet .   HPMC .   analgesics.  

  • 참고문헌 (21)

    1. S. Gupta and L.-J. Crofford, An Update on specific COX-2 inhibitors: The COXIBs, Bulletin on the Rheumatic Disease., 50(1), 5245-5248 (2001) 
    2. Rxlist, Mobic, Meloxicam, Pharmacology & Clinical review, US medicinal information 
    3. M. Pairet, J. van Ryn, H. Schierok, A Mauz, G. Trummlitz and G. Engelhardt, Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. lnflamm Res., 47(6), 270-276 (1998) 
    4. E-M. Andreas, K.-D. Christine, H. Nina, H. Stefan, S. Jens and K.-H. Juergen, Water-so;uble meloxicam granulates, PCT W02004037264 
    5. K. Laura, P. John, C.-R. Eugene and R. Tuula, Nanoparticulate meloxicam formulations, US patent US2004229038 
    6. S. Baroota, S.-P. Agarwal, Meloxicam complexation with ${\beta}$-cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity, 58, 73-74 (2003) 
    7. N.-B. Naidu, K.P.R. Chowdary, K.Y.R. Murthy, Y. Satyanarayana, A.-R. Hayman and G. Heeket, Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems, Journal of Pharmaceutical and Biomedical Analysis, 35, 75-86 (2004) 
    8. M.-M. Ghorab, H.-M. Abdel-Salam, M.-A EI-Sayad and M.-M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation, AAPS Pharm. Sci. Tech., 27(5) , e59 (2004) 
    9. J. Dequeker, and F. degner, Inflammation Research Editorial, lnflamm. Res., 50, Supplement 1 S3-S4 (2001) 
    10. E.-M. Lemmel, W. Bolten, R. Burgos-Vargns, P. Platt, M. Nissila, D. Sahlberg, et al., Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatopl., 24, 282-290 (1997) 
    11. B. Lund, M. Dialel, R. Bluhmki and A double-blind, randomized placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J. Rheumatol, 27, 32-37 (1998) 
    12. D. Vocum, D. Hall, and P. Ruszko, Meloxicam osteoarthritis team. Efficacy and safety of meloxicam in the treatment of osteoarthritis. Arthr Rheum., 42(Suppl), S147 (1999) 
    13. M. Dougados, A. Gueguen, J.-P. Nakache, I. Veys, E.-M. Zeildler, et a!., Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology, 38, 235-244 (1999) 
    14. D. Duchene, D. Wouessidiewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. lnd. Pharm., 16, 2487-2499 (1990) 
    15. O. Berkers, E.Y. Uijioridal, J.-H. Haijnen, A. Bult and W.-J. Underberg, Cyclodextrins in the pharmaceutical field. Drug Dev. lnd. Pharm. 17, 1503-1549 (1991) 
    16. Ludipress, Technical information, BASF Chem. Co., Supersedes issue of October 2001, September, 2003 
    17. Metolose SR (Hypromellose), Technical note, ShinEtsu Chem. Co., issued on October, 2002 
    18. B. Pose-Vilamovo, C. Rodriguez-Tenreiro, J.-F. Rosa dos Santos, J. Vazquez-Doval, A. Concheiro, C. Alvarez-Lorenzo and J.-J. Torres-Labandeira, Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets. J. Control Release. 10;94(2-3), 351-363 (2004) 
    19. R.-O. Williams 3rd, M.-A .Sykora and V. Mahaguna, Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS Pharm. Sci. Tech. Jun, 9;2(2):E8 (2001) 
    20. D.-X. Zhejiang, B. Xue and Y.-X. Ban. Investigation on release model of insoluble drug in hydroxypropyl methycellulose matrix tablets, 33(3), 225-228 (2004) 
    21. R. Banerjee, H. Chakraborty and M. Sarkar, Host-Guest complexation of oxicam NSAIDs with ${\beta}$-cyclodextrin, Biopolymers, 75(4), 355-365 (2004) 

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • NDSL :
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기